BRD4 has attracted attention as a promising anti-cancer drug target due to its strong effect on expression of the transcription factor MYC, which is a well-known pro-oncogenic master regulator and a major driver of wide variety of cancers (Cancer Genome Atlas Research Network, 2011; Cancer Genome Atlas Network, 2012a; Cancer Genome Atlas Network, 2012b; Cancer Genome Atlas Research Network, 2015). The gene discussed is BRD4; the disease is cancer.